Gainers Kandi Technologies Group Inc shares gained 34.34 percent to close at $7.98 on Wednesday after the company reported NHTSA approval of 2 electric vehicle models. Arca Biopharma Inc shares surged 31.27 percent to close at $0.5080 on Wednesday after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support a
Analyst Ratings For Abeona Therapeutics Inc (NASDAQ:ABEO) Today, HC Wainwright reiterated its Buy rating on Abeona Therapeutics Inc (NASDAQ:ABEO) with a price target of $30.00. There are 8 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock. The current consensus rating on Abeona Therapeutics Inc (NASDAQ:ABEO) is Buy w
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 8 th Annual Leerink Partners Global Healthcare Conference on Thursday, February 28, 2019, at 9:30 a.m....
Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, announces it has been recognized by the TSX Venture Exchange in its 2019 Venture 50, a ranking of the strongest companies on TSX Venture Ex
-Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant gram-negative infections, today announced that the Company will be presenting at the following investor conferences:. 8th Annual Leerink Global Healthcare Conference on February 27th, 2019 at...
Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant gram-negative infections, today announced that the New England Journal of Medicine has published the results from the Phase 3 CARE study of plazomicin in a Letter to the Editor. Achaogen's EPIC...
Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant gram-negative infections, today announced that the New England Journal of Medicine has published the results from the Phase 3 EPIC study of ZEMDRI. Wagenlehner, M.D., Director, Clinic for Urology,
SEATTLE- Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the completion of full enrollment in the ORCA-1 trial of cytisinicline. ORCA-1 is the first in Achieve's ORCA Program, which aims to evaluate the effectivenes
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement mediated diseases, today announced the expansion into a second office located at 1777 Sentry Parkway West in Blue Bell, Pa. The approximately 12,000 square-feet office space will serve as.
SAN DIEGO- Adamis Pharmaceuticals Corporation announced today that the article entitled' Higher doses of naloxone are needed in the synthetic opioid era' has been published in the peer reviewed journal Substance Abuse Treatment, Prevention, and Policy. According to statistics published by the Centers for Disease Control and Prevention in 2017, drug
This partnership brings together critical capabilities to allow the commencement of Adial's planned initial Phase 3 trial, with Catalent providing packaging and distribution. Catalent has a robust, global network, with the presence in Europe and the U.S. to provide flexible, integrated clinical supply services for investigational medicinal products
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced the pricing of an underwritten public offering of 2,475,000 shares of its common stock and warrants to purchase up to 1,856,250 shares of the Company's common stock. Maxim Group LLC is acting as the book-r
WiseGuyReports.com adds "Advanced Parenteral Drug Delivery Devices Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2024" reports to its database. WiseGuyReports.com adds "Advanced Parenteral Drug Delivery Devices Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to
Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Thursday, February 28, 2019, at 5:00 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2018, and recent operational highlights.
BioCorRX, a small Anaheim company, believes it can help break this vicious cycle, and the National Institute on Drug Abuse is inclined to agree. The institute part of the National Institutes of Health has awarded BioCorRX a grant to help develop a naltrexone implant to treat what is officially called "opioid use disorder." BioCorRx in Anaheim,
THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 21, 2019/ PRNewswire/ Amgen, Cytokinetics, Incorporated and Servier today announced that METEORIC-HF, the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potenti
WESTMINSTER- ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment on the design of a pivotal Phase 3 clinical..
California Attorney General Xavier Becerra issued the following news release:. California Attorney General Xavier Becerra and Assemblymember Jim Wood today unveiled legislation to help curb increasing drug prices in California. These agreements, known as "pay-for-delay" agreements, have significantly contributed to price increases for prescription.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced that the company will release its operating and financial results for the transition period from October 1, 2018 to December 31, 2018 before the opening of U.S. markets on Monday,
NEW YORK- AzurRx BioPharma, Inc., a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today provided a clinical development and strategic corporate update. Key highlights of OPTION include: Primary endpoint is a six-week non-inferiority, coefficient of fat absorption assessment comparing..
Analyst Ratings For AzurRx BioPharma Inc (NASDAQ:AZRX) Today, HC Wainwright reiterated its Buy rating on AzurRx BioPharma Inc (NASDAQ:AZRX) with a price target of $8.00. There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock. The current consensus rating on AzurRx BioPharma Inc (NASDAQ:AZRX) is Buy with [?]
First commercial program under Bavarian Nordic and Janssen Vaccines& Prevention B.V. collaboration advancing into clinical trials A therapeutic vaccine may represent a novel approach for early treatment and interception of HPV-induced cancers. COPENHAGEN, Denmark, February 21, 2019- Bavarian Nordic A/S today announced that the first patient has bee
-BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today presented its 2018 achievements and corporate priorities for 2019. "The positive Phase 1 data reinforces our position that our lead drug candidate BLU-5937 has the potential to be a best-in-class therapeu
BioDelivery Sciences International, Inc., a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that it will report its fourth quarter and full year 2018 financial results after the close of the U.S. financial markets on Thursday, March 14, 2019. About BioDelivery Scien
NEW HAVEN- Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neuropsychiatric diseases, today announced that it has enrolled its first patient in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in generalized...